BrainEver
Claire Friedel has a diverse work experience, starting in 2002 at Janssen-Cilag as a CRA coordinator for Medical Affairs. Claire then joined UCB pharma in 2004 as a Medical and Scientific Liaison until 2010. From 2010 to 2013, they worked as a Medical advisor at UCB pharma. Claire then transitioned to UCB in 2014, where they held the roles of Medical Education Manager Senior Consultant until 2015, and later as a Medical Manager for Parkinson Disease until 2017. In 2017, they joined BrainEver as a Global Project Leader and subsequently became the Chief Project Officer in 2019.
Claire Friedel completed their Executive MBA at ESCP Business School from 2019 to 2021. Prior to that, they pursued a DESS in Neurobiology & neuropsychology at Université Paris Cité from 2001 to 2002. Claire began their educational journey by attaining a Master's degree in Neurosciences from University Paris VI, which they obtained from 1998 to 2001.
This person is not in any teams
BrainEver
BrainEver’s innovative therapeutic strategy is a translation of the work by Alain Prochiantz and colleagues on brain development and physiology. They demonstrated that homeoproteins, first identified as early developmental regulators, are also active throughout life and control several neuronal functions, including metabolism and epigeneticstability.BrainEver makes the hypothesis that, in patients, homeoprotein administration could durably modify the physiological resistance of surviving neurons while increasing their activity, thus leading to the improvement of clinical symptoms.Different homeoproteins that could be important in different neurodegenerative pathologies are being explored, the most advanced being Engrailed 1 (BREN01) for the treatment of Parkinson Disease and Amyotrophic Lateral Sclerosis (ALS).Beside Engrailed 1 in Parkinson Disease and ALS, BrainEver is currently generating a pipeline of 4 drug candidates targeting other neurodegenerative disease like Huntington Disease and Optic Neuropathies.